- Home
- Companies
- Benevolent
- Products
Benevolent products
Benevolent - The Benevolent Platform
The Benevolent Platform™ is our powerful computational R&D platform. At its core sits our Knowledge Graph, which captures the interconnectivity of all relevant available data and scientific literature. Our suite of exploratory and predictive AI tools allow scientists to interrogate the data and disease networks within the graph, ask biological questions, surface novel insights and triage hypotheses. This allows scientists to visualise the key differentiators between health and disease and pinpoint dysregulated pathways and mechanisms enabling them to identify optimal treatment interventions.
Covid-19
The emerging global threat from COVID-19 demanded immediate action. With cases rising rapidly, we set up a specialist team to use our AI-drug discovery platform to search for existing drugs — already proven safe — that could be repurposed to treat the virus. We are the only AI company to successfully identify a drug to treat COVID-19. Together by building bespoke drug repurposing workflow customisations, we used our Knowledge Graph and AI tools to search for approved drugs that could treat COVID-19, focusing on those that might block the viral infection process. We identified baricitinib — a drug owned by Eli Lilly and approved to treat rheumatoid arthritis — as the strongest treatment candidate. Our hypothesis sparked global clinical trials and the drug we identified is now approved by the FDA to treat COVID-19.
Atopic Dermatitis
Advancing a potent and selective Atopic Dermatitis treatment through the clinic. What is Atopic Dermatitis? Atopic Dermatitis (AD), the most common type of eczema, is a chronic relapsing inflammatory skin disease that results in itchy, red, swollen, and cracked skin. Our work : BEN-2293, a Pan-Trk antagonist, is being developed to treat AD without the need to use topical steroids and designed to address the debilitating itch and inflammation in both adults and children. Progress so far: We are currently studying BEN-2293 in a Phase I/II proof-of-concept, randomised, first-in-human clinical trial in adult patients with mild to moderate disease.
Ulcerative Colitis
Better target discovery and compound design in Ulcerative Colitis. What is UC?: Ulcerative colitis (UC) is a chronic, lifelong disease that causes inflammation and ulceration of the inner lining of the colon and rectum, accompanied by debilitating symptoms. Our work: There is no cure for UC, current treatments have side effects and don’t work on all patients. Our work focuses on developing safer and more effective oral small molecule treatments. Progress so far: For our most advanced UC programme, we identified an AI-generated target with novel mechanisms of action in UC, and rapidly delivered a candidate drug to IND/CTA-enabling studies.